Erenumab – Comprehensive Assessment of Efficacy in (High-Frequency) Episodic MigraineEMBRACE

Key inclusion criteria include: • Age greater than or equal to 18 years upon entry into initial screening. • Documented history of migraine with or without aura according to the International Headache Society (IHS) International Classification of Headache Disorders, Third Edition (ICHD-III) for greater than or equal to 12 months. • Have high-frequency episodic migraine (HFEM): Defined as history of ≥ 7 to < 15 migraine days and < 15 headache days per month on average during the 3 months prior to screening. • History of ≥ 4 migraine attacks of at least moderate severity per month on average during the 3 months prior to screening. • History of treatment failure with at least 1 preventive treatment for migraine. Failure of preventive treatment for migraine is defined as treatment discontinuation due to lack of efficacy, adverse event, or general poor tolerability. • Regular use of an oral triptan (using only eletriptan, rizatriptan, sumatriptan, or zolmitriptan) for acute migraine treatment, and typically initiating acute treatment with an oral triptan on > 50% of attacks of at least moderate pain intensity. Regular use is defined as ≥ 4 days of oral triptan use per month during the 3 months prior to screening. Key exclusion criteria include: • History of hemiplegic migraine, cluster headache, or other trigeminal autonomic cephalalgia. • Has any medical contraindication to the use of an oral triptan. • Previously treated with erenumab. • Previously treated with a gepant (small molecule calcitonin gene related peptide receptor [CGRP-R] antagonist) in a preventive fashion in a manner consistent with migraine prevention that either: a. In the opinion of the investigator, did not offer any evidence of a therapeutic response or b. Was discontinued for less than 12 weeks from the date of initial screening or c. Was previously discontinued due to a known adverse drug reaction • Currently being treated with lasmiditan and/or a gepant in the acute setting. • No therapeutic response with greater than 4 of the defined medication categories after an adequate therapeutic trial. • Currently has a history of consistent excellent response to oral triptans, defined as achievement of pain-freedom in ≤ 1 hour for ≥ 50% of treated attacks of at least moderate pain intensity during the 3 months prior to screening. • Use of triptans administered via a non-oral (e.g. subcutaneous [SC] or intranasal delivery systems) or sublingual route at the time of screening, during the run-in and baseline periods, and throughout the study duration.